Ectris - Arguments For It - Arguments Against It

Argument for Medical Treatment of Female HSDD


Ectris and Female Hypoactive Sexual Desire Disorder bring with it more topics for discussion than its male counterpart Erectile Dysfunction. ED and treatments for in men is based more on blood flow to the male sexual organ allowing it to perform intercourse. With Female HSDD, there can be more emotional and metal issues that can get in the way of a woman desiring sexual encounters. Regardless if 1-2 in 10 women experience HSDD to some form and they can't figure out why their sexual desire decreased so much why not a pill that can help if it is available?
There is a fix for men, why not a fix for women? Woman desire the same kind of sexual satisfaction that males do but woman's sexual make up substantially differs from men's. Men can generally be sexually turned on quickly where as with woman it usually takes more time. While HSDD in men is relatively low, in women then numbers are larger and it can be a factor that interferes with her ability to connect to her partner. Sex is a way to connect to your partner for a woman, if there is something that can increase the desire to do this, it could be a fascinating thing. Obviously a substance like Ectris would have to be taken as recommended by a medical doctor and like any drug in existence, to only be taken if it is prescribed to you.
Ectris has the ability to make many women run to their doctors and want to be put on it. Whatever the reasons for causing Female HSDD, a once a day pill could really provide the spark in a woman's love life. There is debate what causes female sexual problems but they often stem from issues to do with ones schedule. For some women, between a job, children, household chores and the stresses that come with them it can be easy to become burnt out and not feel like having any sexual relations with your partner. But others argue that some women in these situations are not affected so it could be genetic or unknown reasons why there is a chemical imbalance. And of course there could be relational issues preventing sexual feelings.
An important point to make with the argument for medical treatment of HSDD is that it becomes an issue that a woman is not feeling pressured into taking it because of her partner. If the woman is thinking that her desire has fallen radically and that this is a treatment she would like to explore than it could be a good thing. There is room for abuse if someone is feeling forced to take a medication they don't think they need.

Argument against treating Low Female Libido with Ectris

HSDD is a new term given to woman said to have a low libido. Their desire for sexual encounters they once had seemed to have pretty much faded away. But the thought of treating this with a drug is troubling for some. There is good reason to believe that the vast majority of females not desiring sexual encounters are due to a relational breakdown with their partner and deeper rooted issues psychologically and that no drugs should be introduced to solve this problem when it should not be touched by pharmaceuticals.
Some people are saying that the HSDD is either completely made up for a condition that does not exist and that the actual numbers of women who apparently suffer from this are a fabricated attempt by big pharma to push medication on any unfavorable condition in life. Women are very different in their sexual make up. Men can often be turned on quickly and need no emotional contact with their partner to enjoy sex. Woman on the other hand most often need an emotional connection and good feelings towards their partner to enjoy sexual encounters. If a woman feels she is missing this emotional connection with her mate, she most likely will not want to have sex. This can often be cultivated by the male by "treating her nicely" and spending time with her. But if a male simply wants sex with his partner and she has not felt these, it cannot simply be treated with a pill and that solves all issues. Woman need love, affection and intimacy from their partner to enjoy sex, males do not.
A possible abuse issue is for men to force their partner into taking this medication to increase their desire. A man could simply think that if their woman is not interested in sex when he is that it is need for a prescription. This is due to the thinking on the male end that females work the same way that males do regarding sexual response. There is a need to educate men on how a woman works sexually to help this problem, not drugs. It is also a difficult "disease" to quantify, if you desire sex less than someone else does it require a medicine? What if a woman is satisfied with the number or sexual encounters she has with her man? It is hard to define a normal sex drive and what needs help.

==========================================================================
Ectris, a Medical Treatment for Female Hypoactive Sexual Desire Disorder

Ectris is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Ectris is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman's sexual craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues. Ectris (Girosa ), created by Boehringer Ingelheim, a German Pharmaceutical company, was originally being created as an anti-depressant but after testing for such was found to be a poor treatment for depression. Similarly how Viagra® was being experimented with originally to treat high blood pressure and angina (a heart condition). Interestingly while females where being questioned about their trial experiences for depression, a large number noticed an unexpected positive side effect from Ectris. They discovered that many woman where reporting more sexual interest and overall satisfying sexual experiences than before. Apparently some woman who where taking part in the trials didn't want to stop the testing based on this fact alone. This led the company to clinically testing this new compound for this exact reason. Can it actually increase a woman's desire for sex? Boehringer Ingelheim set out to test Flibanserin with several clinical tests. One test with almost 2000 women (half taking the placebo) was performed over a 24 week period. These women where pre-menopausal, of different walks of life, and none had any majorly depressive disorder. This was to ensure that Ectris was not working as a result of depressed woman simply feeling better thus an increase in sexual desires. What was found during this testing was that woman on average said that their pleasing sexual experiences went from 2.8 times a month to 4.5 times a month. However also during this time woman on the placebo experienced an increase to 3.7 times a month. The difference being almost 1 more sexual enjoyable occasion per month. They also determined that generally the medication started working after around a 4 week period being taken once per day, usually before bedtime. The amount of Flibanserin what was determined most appropriate was 100mg. Although these reports are based strictly on a users self report, later MRI's done on classified HSDD woman showed that there actually is chemical balance disordered within the brain and blood not flowing to those areas as well. Side effects that where reported by some of the users where usually low to moderate. These where dizziness, anxiety, fatigue, dry mouth, insomnia, nausea. Not everyone who partook in the study had any of these but there were more occasions of these being reported compared to the placebo group and due to the fact that this compound is fairly new, there have not been nor could there have been any long term studies on side effects.December 28th 2006It was reported that Boehringer Ingelheim accidentally discovered Ectris' potential while trying to create a quick acting Anti-Depressant. Because many anti-depressants actually can lessen ones libido, during the testing they asked people if they had this. The men in the testing did not have any altered response but many women did. They also reported that they have started four large clinical trials with 5,000 women in 220 locations. These were named Orchid®, Daisy®, Violet® and Dahlia®. If all goes well they could seek FDA approval sometime in 2009.November 16th 2009It is reported that the four phase 3 trials for Flibanserin where reported at the European Society for Sexual Medicine. Results averaged in these tests showed woman had an increase in satisfying sexual encounters from 2.8 per month to 4.5 times per month. However the placebo group had an increase as well from 2.8 per month to 3.7 times a month. Side effects reported where some occasional mid to moderate nausea, dizziness, insomnia and drowsiness. Ectris has not at this time been submitted to the FDA for approval. It may potentially be done so within 2 years. If it is, there are not guarantees that the FDA will approve its use. There have been rumors that it could become available in the UK by the Spring of 2011.May 18th 2010Boehringer Ingelheim Pharmaceuticals reported today that information from a phase three trial confirmed that a larger portion of pre-menopausal women with HSDD taking 100mg Ectris (Flibanserin) reported meaningful improvements compared to the group taking a placebo.Of 1,378 pre-menopausal women patients suffering from HSDD taking flibanserin 100mg provided feedback from an indepth questionnaire stating that 48.3% after 24 weeks of treatment reported different levels of improvement as compared to 30.3% of the placebo takers

. 40.5% of the Ectris takers also reported a meaningful benefit from the medication as compared to 25.2% of the placebo group. On the Proposed date of June 18th 2010, a FDA's Reproductive Health Drugs Advisory Committee will determine on whether or not to propose the approval of Flibanserin to the FDA.June 16th 2010Today the FDA questioned the safety and success of Flibanserin and find that the drug was considered moderate for its acceptability. Other issues they were concerned about were Fatigue, sedation and drowsiness as they had been reported often during testing. There are also reported numerous drug interactions that may need more than just labeling to warn women. The FDA stated that "overall response rate...is not particularly compelling." also they stated concerns when the drug was taken with alcohol, antidepressants and hormonal contraceptives. June 18th 2010The FDA advisory panel voted 10 to one that flibanserin was not significantly better than a placebo, and unanimously that the benefits did not outweigh side effects like dizziness, nausea and fatigue... Although this was rejected in the USA, it is unsure what the Boehringer Ingelheim's plans are now. If they decide to pursue it in other countries or what their next step is regarding Ectris.We update this page

with any significant news as it becomes available.


Although Ectris Has not been approved, This product guarantees a better female sexual arousal experience or your Money Back!The most indulgent libido enhancement guarantee in the business

As Seen on hit tv show "The Doctors" See Video Clip Here90 Days Money Back Gurantee!Find out More about Her Solution Gel

Ectris Anti-Depressant

No one can dispute the success of the little blue pill we all call Viagra. It is the most popular prescription medication in the world, but it didn't start out that way. Sildenafil, better known as Viagra, was a hypertension medication when Pfizer developed it in the early 1990s, but clinical tests revealed it had the ability to increase blood flow to the small blood vessel in and around the penis, and the rest as they say is history.

The German pharmaceutical company Boehringer Ingelheim is experiencing a similar situation with Ectris the anti-depressant drug. Several years ago Boehringer introduced Ectris as an anti-depressant, but the first clinical tests on over two thousand women showed that Flibanserin had the ability to increase sexual fantasies and desires in women suffering from some type of female sexual dysfunction (FSD).

The results of those first clinical studies convinced Boehringer to change their marketing strategy from Ectris the anti-depressant to Ectris the female libido enhancer. The company began four clinical studies on the drug in order to apply for FDA approval. Over five thousand women in three hundred and fifty different locations around the world participated in clinical trials and the results have been extremely encouraging.

Boehringer believes that Ectris , the anti-depressant, can be as popular as Viagra and may even have the potential to replace Viagra as the most popular prescription medication in the world once the FDA approves it for medical use. Clinical data shows that women suffering with hypoactive sexual desire disorder and sexual arousal disorder increase their sexually satisfying experiences from three to five a month. Women in the studies also report more sexual fantasies and desires when 100mg of Ectris is used for at least forty weeks.

Ectris the Anti-depressant does Create Some Interesting Side Effects
Ectris the antidepressant turned sexual stimulator has dopamine D4 receptors and serotonin 5-HT receptors as ingredients, and those agents can cause side effects when they enter the body in pill form. Those chemicals are naturally produced in the body, but due to varying hormonal levels those agents can impact the body in different ways.

No one knows how Ectris the ex-antidepressant stimulates the libido, but some researchers believe that an increase in dopamine production and decrease in serotonin production stimulates the central nervous system and the body responds by increasing sexual hormone production even though the ex-antidepressant Ectris is non-hormonal.

Ectris could be approved next week by the FDA

Washington: Next week, the FDA will vote on whether the female libido enhancing drug Ectris should be voted in or out. If it could mean a business of 2 million dollars in US markets alone.

The Food and Drug Administration will vote on what's being called 'female viagra', a drug that could be a boon to many women suffering from low sex drives across the globe but is still ensnared by controversy.

The pill is designed to treat a condition identified in an estimated 10 percent to 30 percent of women as hypoactive sexual desire disorder or HSDD - characterised by lack of sexual desire or fantasies, causing emotional distress, a rather vague diagnosis.

The pill, however, comes with side effects, which include insomnia, nausea and dizziness. As always, women will need to decide whether the risks versus the benefits compared to other treatment alternatives are worth it for them.

"What we don't know is what's normal versus what's not normal. You can't label someone who has a low sex drive necessarily as abnormal," CBS News quoted Dr. Bruce Levine of Phoenix OBGYN Associates as saying.

Critics are hammering the drug, saying that customers are being tempted into buying something they don't need and can solve by other inexpensive methods.

"We call that disease mongering, creating a disease when there is no disease in order to sell an expensive product," said Leonore Tiefer of New York University's School of Medicine.

"There are a lot of inexpensive products like a glass of wine or a massage."

"I would say it's definitely improved," said Alicia, who signed for the clinical trial of the drug after being miserable for a long time.

"I find myself initiating things more when I feel like I'm ready to have sex." (ANI)

SEARCH

What Is Ectris (Flibanserin)?

What Is Ectris (Flibanserin, Girosa)?

Ectris (Flibanserin, Girosa) could be the first oral product for the treatment of HSDD (hypoactive sexual desire disorder in menopausal women) in the U.S.
Ectris (Flibanserin) works in the central nervous system, which regulates sexual desire.
Ectris (Flibanserin) acts as a 5-HT1A serotonin receptor agonist and 5-HT2A serotonin receptor antagonist.


Clinical studies are underway to better understand this investigational compound and how it may impact women with Hypoactive Sexual Desire Disorder (HSDD).


Ectris (flibanserin) Phase III Study Results

Ectris (Flibanserin) Phase III trials study presented at the Congress of the European Society for Sexual Medicine in Lyon, shows positive results with pre-menopausal women taking Ectris (flibanserin 100mg) once-daily at bedtime, increasing the number of Satisfying Sexual Events (SSEs) and decreasing significantly the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
Phase III Clinical Trial Results in North America
Analysis of 1,378 pre-menopausal women taking Ectris (Flibanserin 100mg) during 24-week study period, shows significant increase in the frequency of Satisfying Sexual Events (SSEs) per month from 2.8 at baseline to 4.5 versus placebo 2.7 at baseline increasing to 3.7.
Other key secondary endpoints showed Ectris (flibanserin) significantly improved sexual functioning as measured by data from the desire domain of the Female Sexual Function Index (FSFI).
Recently Boehringer Ingelheim presented new data from Phase III clinical trials of Ectris (Flibanserin 100 mg) at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in San Francisco.
Ectris
(Flibanserin 100 mg)
New Phase III Data in USA reported positive results
Safety Analysis
Ectris (flibanserin 100mg) adverse events were mild to moderate, emerged during the first 14 days of treatment and resolved with continued treatment.
The most common adverse drug reactions reported by more women on Ectris (flibanserin) than on placebo included dizziness, nausea, fatigue, somnolence and insomnia.
Boehringer Ingelheim was conducting Phase III clinical trials evaluating Ectris (Flibanserin) in over 2,000 women at 360 locations in the USA, Canada and Europe.

Flibanserin’s effects are believed to improve a woman’s decreased sexual desire gradually over time and a Phase III study results programme show that Ectris (flibanserin 100mg) is well-tolerated and effective in pre-menopausal women suffering Hypoactive Sexual Desire Disorder (HSDD).


USA Flibanserin 100 mg active clinical trials

Women 18 to 55 years of age diagnosed with Hypoactive Sexual Desire Disorder with a monogamous heterosexual relationship for at least one year, can now participate in clinical trials across the USA and Canada to test the safety and efficacy of flibanserin 100 mg in naturally postmenopausal women.
For further information visit the following link:

http://clinicaltrials.gov/ct2/results?term=flibanserin&recr=Open&s



Ectris (Flibanserin, Girosa ) Side Effects
Phase III Clinical Trials ResultsGirosa (flibanserin 100mg) adverse events were mild to moderate, emerged during the first 14 days of treatment and resolved with continued treatment.
The most common side effects reported by more women on Ectris (flibanserin) than on placebo included dizziness, nausea, fatigue, somnolence and insomnia.

Can I buy Ectris Girosa (flibanserin, Girosa )?
No, Ectris (Flibanserin) is not yet available for sale.

Ectris / Girosa (flibanserin) libido pills for women

Ectris / Girosa (flibanserin) libido pills for women

Ectris (Flibanserin) is an non-hormonal compound being studied as a potential oral daily treatment for pre-menopausal women suffering Hypoactive Sexual Desire Disorder (HSDD).
Ectris (Flibanserin) could be the first oral product for the treatment of HSDD (hypoactive sexual desire disorder in menopausal women) in the U.S.
"It's essentially a drug that raises dopamine, the chemical that increases interest," said Irwin Goldstein of Alvarado Hospital's Sexual Medicine Center in San Diego.
Ectris / Girosa (Flibanserin) works on the central nervous system and acts as a 5-HT1A serotonin receptor agonist and 5-HT2A serotonin receptor antagonist.
Recent Phase III clinical trials results presented at the Congress of the European Society for Sexual Medicine in Lyon, demonstrated that Girosa (flibanserin 100mg) taken once-daily at bedtime, increase the number of Satisfying Sexual Events (SSEs) and decrease significantly the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

‘Viagra’ for women to hit the shelves soon

Good news for women who want to perk up the action in their bedroom-the Food and Drug Administration committee is thinking of endorsing the first pill designed to do for women what Viagra does for men-boost their sex lives.
A German pharmaceutical giant wants to sell a drug with the decidedly unsexy name “flibanserin,” which has shown prowess for sparking a woman’s sexual desire by fiddling with her brain chemicals.
The FDA’s Reproductive Health Drugs Advisory Committee will meet on June 18 to consider the request.
But the prospect of the drug’s approval has already triggered debate over whether the medication, like others in the pipeline, represents a long-sought step toward equity for women’s health or the latest example of the pharmaceutical industry fabricating a questionable disorder to sell unnecessary and potentially dangerous drugs.
“Achieving a happy and healthy sex life can be a real and important problem for some women. But we have lots of questions about the ‘pink Viagra,’” the Washington Post quoted Amy Allina of the National Women’s Health Network, a Washington-based advocacy group, as saying.
Viagra’s catapult to blockbuster status after its 1998 approval set off a flurry of interest in me-too medications for women.
However, drugmaker Pfizer’s hopes that its “little blue pill” would also ignite female libido fizzled, making it clear that a woman’s sexuality is more complicated than a man’s.
But, Germany’s Boehringer Ingelheim is optimistic that flibanserin is on the verge of becoming the first prescription medication to tap what some have estimated could be a 2 billion dollar market in the United States alone.
“We believe women deserve options and we’re hoping flibanserin may represent a safe and effective option for many women,” said Michael Sand, who heads the company’s clinical research on flibanserin.
Scientists found that flibanserin, developed as an antidepressant, was ineffective for treatment of depression.
But the drug appeared to produce an unexpected side effect: boosting women’s libido.
This prompted the company to study it for hypoactive sexual desire disorder, or HSDD, an otherwise unexplained loss of sexual thoughts, fantasies and desire that can cause significant emotional distress.
Some research suggests 10 percent of women may suffer from HSDD.
“It’s not that they are averse to sex. It’s just that they don’t care about it. They just stop thinking about it. It’s like a switch has been flipped. It’s a loss for them. They miss it. And they want it back,” said Anita H. Clayton, a professor of psychiatry and neurobehavioral sciences at the University of Virginia who has studied the drug for the company. (ANI)

Ectris

Ectris is a drug produced by Boehringer Ingelheim. It is currently being investigated as a drug for women with decreased sexual desire. It is a 5-HT1A receptor full agonist, 5-HT2A receptor antagonist, and D4 receptor very weak partial agonist that had initially been developed as an antidepressant. As with Viagra, the effects of Ectris were discovered serendipitously after it was trialled as an antidepressant. Although touted as "Female Viagra" Ectris does not work like any PDE5 inhibitors. Ectris does not play a part in transferring increased amounts of blood to the female genital region as PDE5 inhibitors do to the male genital region. Female HSDD (Hypoactive Sexual Desire Disorder) is not similar to its male counterpart Erectile Dysfunction in the way it is treated. Some have argued that Female Sexual Dysfunction is merely Disease Mongering and a ploy to expand a market for sex drugs for women and to medicalize women's sexuality.